Ellis John, Gow Sheryl, West Keith, Waldner Cheryl, Rhodes Carrie, Mutwiri George, Rosenberg Helene
Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK S7N 5B4, Canada.
J Am Vet Med Assoc. 2007 Jan 15;230(2):233-43. doi: 10.2460/javma.230.2.233.
To determine whether single-fraction and combination modified-live bovine respiratory syncytial virus (BRSV) vaccines commercially licensed for parenteral administration could stimulate protective immunity in calves after intranasal administration.
Randomized controlled trial.
39 calves.
Calves were separated from dams at birth, fed colostrum with a minimal concentration of antibodies against BRSV, and maintained in isolation. In 2 preliminary experiments, 9-week-old calves received 1 (n = 3) or 2 (3) doses of a single-component, modified-live BRSV vaccine or no vaccine (8 control calves in each experiment), and were challenged with BRSV 21 days after vaccination. In a third experiment, 2-week-old calves received combination modified-live virus (MLV) vaccines with or without BRSV and calves were challenged with BRSV 8 days later. Calves were euthanized, and lung lesions were measured. Immune responses, including serum and nasal antibody and nasal interferon-alpha concentrations, were assessed.
BRSV challenge induced signs of severe clinical respiratory tract disease, including death and pulmonary lesions in unvaccinated calves and in calves that received a combination viral vaccine without BRSV. Pulmonary lesions were significantly less severe in BRSV-challenged calves that received single or combination BRSV vaccines. The proportion of calves that shed virus and the peak virus titer was decreased, compared with control calves. Protection was associated with mucosal IgA antibody responses after challenge.
Single and combination BRSV vaccines administered intranasally provided clinical protection and sparing of pulmonary tissue similar to that detected in response to parenteral delivery of combination MLV and inactivated BRSV vaccines previously assessed in the same challenge model.
确定经胃肠外给药获得商业许可的单剂量和联合减毒活牛呼吸道合胞病毒(BRSV)疫苗经鼻内给药后是否能刺激犊牛产生保护性免疫。
随机对照试验。
39头犊牛。
犊牛出生后即与母牛分开,喂食含有最低浓度抗BRSV抗体的初乳,并单独饲养。在2项初步实验中,9周龄的犊牛接受1剂(n = 3)或2剂(n = 3)单组分减毒活BRSV疫苗或不接种疫苗(每项实验8头对照犊牛),并在接种疫苗21天后用BRSV进行攻毒。在第3项实验中,2周龄的犊牛接受含或不含BRSV的联合减毒活病毒(MLV)疫苗,8天后用BRSV进行攻毒。对犊牛实施安乐死,并测量肺部病变情况。评估免疫反应,包括血清和鼻腔抗体以及鼻腔α干扰素浓度。
BRSV攻毒在未接种疫苗的犊牛以及接受不含BRSV的联合病毒疫苗的犊牛中引发了严重临床呼吸道疾病的症状,包括死亡和肺部病变。接受单剂量或联合BRSV疫苗的BRSV攻毒犊牛的肺部病变严重程度显著较低。与对照犊牛相比,排毒犊牛的比例和病毒滴度峰值均有所降低。保护作用与攻毒后黏膜IgA抗体反应有关。
经鼻内给药的单剂量和联合BRSV疫苗提供了临床保护,并使肺组织免受损伤,这与在同一攻毒模型中先前评估的经胃肠外给药的联合MLV和灭活BRSV疫苗所检测到的情况相似。